Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE versus OTREXUP PFS.
METHOTREXATE vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Folate antimetabolite; inhibits dihydrofolate reductase (DHFR), blocking conversion of dihydrofolate (DHF) to tetrahydrofolate (THF), thereby inhibiting DNA synthesis, repair, and cellular replication. Also inhibits thymidylate synthetase and purine synthesis.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
7.5-25 mg orally once weekly; alternatively, 10-25 mg intramuscularly, intravenously, or subcutaneously once weekly.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Clinical Note
moderateMethotrexate + Digoxin
"Methotrexate may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateMethotrexate + Digitoxin
"Methotrexate may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateMethotrexate + Deslanoside
"Methotrexate may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateMethotrexate + Acetyldigitoxin
"Methotrexate may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 3-10 hours (low dose) to 8-15 hours (high dose); clinical context: prolonged to 24-48 hours in renal impairment, third-space effusions, or polyglutamation. Delayed elimination due to enterohepatic recirculation.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <10% as metabolites (7-hydroxymethotrexate).
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite